natgillin/translations-raw huggingface dataset:
No tipranavir with ritonavir dose adjustment is required.
Nije potrebno podešavanje doze kombinacije tipranavira s ritonavirom.
In such cases no dosage adjustment of abacavir can be recommended (see section
U takvom slučaju, ne treba prilagođavati dozu abakavira (vidjeti dio 4.4).
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose.
Tijekom antiretrovirusne terapije mogu se povećati tjelesna težina i povisiti razine lipida i glukoze u krvi (vidjeti dio 4.4).
The following medicines are not recommended: - fluticasone (used to treat asthma) - atorvastatin (used to lower blood cholesterol) - salmeterol (used to achieve long-term asthma control, bronchospasm prevention with COPD) - bosentan (used to treat pulmonary artery hypertension) - halofantrine or lumefantrine (used to treat malaria) - tolterodine (used to treat overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence)) - boceprevir and telaprevir (used to treat hepatitis C) - cobicistat and products containing cobicistat (used to increase effectiveness of HIV medicines).
Ne preporučuju se sljedeći lijekovi: - flutikazon (primjenjuje se u liječenju astme) - atorvastatin (primjenjuje se za snižavanje kolesterola u krvi) - salmeterol (primjenjuje se za postizanje dugotrajne kontrole astme, prevenciju bronhospazma u kroničnoj opstruktivnoj bolesti pluća) - bosentan (primjenjuje se u liječenju plućne hipertenzije) - halofantrin ili lumefantrin (primjenjuju se u liječenju malarije) - tolterodin (primjenjuje se u liječenju preaktivnog mjehura (sa simptomima učestalog mokrenja,
Carbamazepine total* Cmax ↑ 13% Carbamazepine total* AUC ↑ 16% Carbamazepine total* Cmin ↑ 23%
Antiepileptici Karbamazepin 200 mg BID Karbamazepin ukupni* Cmax ↑ 13% Karbamazepin ukupni* AUC ↑ 16% Karbamazepin ukupni * Cmin ↑ 23%
Therefore, the co-administration of tipranavir, co-administered with low dose ritonavir, with protease inhibitors is not recommended.
Stoga se ne preporučuje istodobna primjena tipranavira s niskom dozom ritonavira, i inhibitora proteaze.
Combination of rifampicin with Aptivus with concomitant low dose ritonavir is contraindicated (see section 4.5).
Kombinacija rifampicina s Aptivusom i niskom dozom ritonavira je kontraindicirana (vidjeti dio 4.5).
Steady-state tipranavir/r Digoxin Cmax ↓ 20% Digoxin AUC ↔
Tipranavir/r u stanju ravnoteže Digoksin Cmax ↓ 20% Digoksin AUC ↔
Macrogol
Ergotamin
Co-administration of Aptivus, coadministered with low dose ritonavir, and pravastatin should be initiated with the lowest dose (10 mg/day) of pravastatin, titrated to treatment response, and accompanied with careful clinical monitoring for pravastatin associated symptoms as described in the label of pravastatin.
Istodobna primjena Aptivusa s niskom dozom ritonavira i pravastatina počinje s najnižom dozom (10 mg/dan) pravastatina, titriranom do terapijskog odgovora, te uz pažljivo kliničko praćenje radi nuspojava pravastatina.
Co-administration of atorvastatin and Aptivus, co-administered with low dose ritonavir, is not recommended.
Istodobna primjena atorvastatina i Aptivusa s niskom dozom ritonavira se ne preporučuje.
Increased monitoring (i.e. prior to initiation of therapy, every two weeks during the first three months of treatment, then monthly until 48 weeks, and then every eight to twelve weeks thereafter) is warranted when Aptivus and low dose ritonavir are administered to patients with elevated ASAT and ALAT levels, mild hepatic impairment, chronic hepatitis B or C, or other underlying liver disease.
U bolesnika s povišenim vrijednostima AST/ALT, blagim oštećenjem jetre, kroničnim hepatitisom B ili C, ili drugom bolešću jetre, praćenje jetrene funkcije mora biti pojačano (tj. prije početka liječenja, svaka dva tjedna tijekom prva tri mjeseca liječenja, zatim jednom mjesečno do 48 tjedana, i nakon toga svakih osam do dvanaest tjedana).
Inhibition of CYP 2D6 by tipranavir/r
Inhibicija CYP 2D6 putem tipranavira/r
Zidovudine Cmax ↓ 49% Zidovudine AUC ↓ 36%
Zidovudin Cmax ↓ 49% Zidovudin AUC ↓ 36%
If the combination is nevertheless considered necessary, a monitoring of the plasma levels of amprenavir is strongly encouraged (see section
Ako se ta kombinacija ipak smatra potrebnom, valja pratiti vrijednosti amprenavira u plazmi (vidjeti dio
Induction of CYP 1A2 by tipranavir/r
Indukcija CYP 1A2 tipranavirom/r
Through 48 weeks of treatment, the proportion of patients in the tipranavir with ritonavir arm compared to the comparator PI/ritonavir arm with HIV-1 RNA < 400 copies/ml was 30% and 14% respectively, and with HIV-1 RNA < 50 copies/ml was 23% and 10% respectively.
IP/ritonavir skupinu 14% dok je udio bolesnika s HIV-1 RNA <50 kopija/ml iznosio 23% za ispitivanu i 10% za kontrolnu skupinu.
Rash consists of one or more of the preferred terms of rash, drug eruption, rash macular, rash papular, erythema, rash maculo-papular, rash pruritic, and urticaria.
Jedan ili više preferiranih termina: osip, medikamentozna erupcija, makularni osip, papularni osip, eritem, makulopapularni osip, pruritički osip ili urtikarija.
Concomitant use of Aptivus, coadministered with low dose ritonavir, and rifampicin is contraindicated (see section 4.3).
Istodobna primjena Aptivusa s niskom dozom ritonavira i rifampicina je kontraindicirana (vidjeti dio 4.3).
Rash gamma GT increased ALAT increased
Povišeni gama- GT Povišeni ALT Anemija
- omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole (proton pump inhibitors used to reduce the gastric acid production) - metronidazole (used to treat infections) - disulfiram (used to treat alcohol dependence) - buprenorphine/naloxone (medicines used to treat severe pain) - cyclosporin, tacrolimus, sirolimus (used to prevent organ rejection (to suppress the immune system)) - warfarin (used to treat and prevent thrombosis) - digoxin (used to treat heart arrhythmias and heart failure) - antifungal medications including fluconazole, itraconazole, ketoconazole or voriconazole
Ne smije Vam se propisati tadalafil dok ne prođe 7 ili više dana od početka uzimanja Aptivusa. - omeprazol, esomeprazol, lanzoprazol, pantoprazol, rabeprazol (inhibitori protonske pumpe koji se primjenjuju za smanjenje proizvodnje želučane kiseline) - metronidazol (primjenuje se u liječenju infekcija) - disulfiram (primjenjuje se u liječenju ovisnosti o alkoholu) - buprenorfin/nalokson (lijekovi koji se primjenjuju za liječenje teške boli) - ciklosporin, takrolimus, sirolimus (primjenjuju se za sprječavanje odbacivanja organa (za supresiju imunološkog sustava)) - varfarin (primjenjuje se u liječenju i prevenciji tromboze) - digoksin (primjenjuje se u liječenju srčanih aritmija i zatajenja srca) - lijekovi za liječenje gljivičnih infekcija uključujući flukonazol, itrakonazol, ketokonazol ili vorikonazol
A safe and effective dose has not been established when used with Aptivus, co-administered with low dose ritonavir.
Sigurna i učinkovita doza tadalafila kada se primjenjuje s Aptivusom uz nisku dozu ritonavira nije utvrđena.
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with Aptivus/ritonavir is required (see section 4.4).
Preporučuje se sniženje doze kolhicina ili prekid liječenja kolhicinom za bolesnike s urednom funkcijom bubrega ili jetre u slučaju potrebe liječenja
Always take this medicine in combination with other antiretroviral medicines.
Uvijek ćete morati uzimati Aptivus u kombinaciji s drugim antiretrovirusnim lijekovima.
Skin and subcutaneous tissue disorders common rash uncommon pruritus, exanthem
Poremećaji kože i potkožnog tkiva često osip manje često pruritus, egzantem
Increasing baseline phenotypic fold change to tipranavir in isolates is correlated to decreasing virological response.
Viša razina fenotipske otpornosti na tipranavir ustanovljena prije početka liječenja združena je s nižom stopom virološkog odgovora.
Further dosage reduction may be necessary.
Dozu rifabutina može biti potrebno dodatno sniziti.
These occur particularly when Aptivus or other protease inhibitors are taken together with nucleoside analogues.
Prijavljeni su slučajevi bolova u mišićima, osjetljivosti ili slabosti, koji se pojavljuju osobito kad se Aptivus ili drugi inhibitori uzimaju zajedno s nukleozidnim analozima.
Dyspepsia
Propafenon
The concomitant use of Aptivus, co-administered with low dose ritonavir, with pimozide, sertindole, quetiapine or lurasidone is contraindicated due to potential serious and/or life threatening events, including coma (see section
Istodobna primjena Aptivusa s niskom dozom ritonavira i pimozida, sertindola, kvetiapina ili lurasidona je kontraindicirana zbog potencijalnih teških i/ili fatalnih događaja, uključujući komu (vidjeti dio 4.3)
The clinical relevance of this reduction in saquinavir concentrations has not been established.
Klinički značaj ovog smanjenja koncentracija sakvinavira nije utvrđen.
The clinical relevance of this reduction in lopinavir concentrations has not been established.
Klinički značaj ovog smanjenja koncentracija lopinavira nije utvrđen.
Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir, is expected to increase pimozide, sertindole, quetiapine and lurasidone concentrations.
Temeljem teoretskih razmatranja, očekuje se da tipranavir u primjeni s niskom dozom ritonavira, povećava koncentracije pimozida, sertindola, kvetiapina i lurasidona.
RESIST-1 and RESIST-2 are ongoing, randomised, open-label, multicentre studies in HIV-positive, triple-class experienced patients, evaluating treatment with 500 mg tipranavir co-administered with low dose ritonavir (200 mg; twice daily) plus an optimised background regimen (OBR) individually defined for each patient based on genotypic resistance testing and patient history.
Ocjenjivani su učinci 500 mg tipranavira s niskom dozom ritonavira (200 mg; dvaput dnevno) dodanih na osnovni optimizirani režim (optimized background regimen, OBR) koji je individualno određen za svakog bolesnika temeljem genotipskog testiranja rezistencije virusa i anamneze bolesnika.
Concomitant use of salmeterol and Aptivus, co-administered with low dose ritonavir, is not recommended (see section 4.5).
Salmeterol Istodobna primjena salmeterola i Aptivusa s niskom dozom ritonavira se ne preporuča (vidjeti dio 4.5).
Grade 3 or 4 elevations of triglycerides occurred more frequently in the tipranavir with ritonavir arm compared with the comparator arm. At 48 weeks these rates were 25.2% of patients in the tipranavir with ritonavir arm and 15.6% in the comparator arm.
Nakon 48 tjedana ove stope su bile 25,2% bolesnika na režimu tipranavir s ritonavirom te 15,6% u komparatorskom režimu.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer responsible for batch release Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany.
Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet Boehringer Ingelheim Pharma GmbH & Co.
- Abnormal liver function - Hepatitis and fatty liver - Liver failure.
- Abnormalna funkcija jetre - hepatitis i masna jetra - zatajenje jetre, što može dovesti do smrti - povišene vrijednosti bilirubina u krvi (razgradni produkt hemoglobina)
Tipranavir, co-administered with low dose ritonavir, is expected to increase desipramine concentrations
Očekuje se da tipranavir u primjeni s niskom dozom ritonavira povećava koncentracije dezipramina.
Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir, is expected to increase halofantrine and lumefantrine concentrations.
Temeljem teoretskih razmatranja, očekuje se da tipranavir u primjeni s niskom dozom ritonavira povećava koncentracije halofantrina i lumefantrina.
Combination with Aptivus, coadministered with low dose ritonavir, is not recommended (see section 4.4)
Kombinacija s Aptivusom s niskom dozom ritonavira se ne preporučuje (vidjeti dio 4.4)
Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir, is expected to increase astemizole and terfenadine concentrations.
Temeljem teoretskih razmatranja, očekuje se da tipranavir s niskom dozom ritonavira povećava koncentracije astemizola i terfenadina.
Concomitant use of Aptivus, coadministered with low dose ritonavir, and oral midazolam is contra-indicated (see section 4.3).
Istodobna primjena Aptivusa s niskom dozom ritonavira i oralnog midazolama je kontraindicirana (vidjeti dio 4.3).
CYP 3A4 inhibition and induction by tipranavir/r
CYP 3A4 inhibicija i indukcija putem tipranavira/r
Fusion inhibitors Enfuvirtide No interaction study
Inhibitori fuzije Enfuvirtid
If the combination is nevertheless considered necessary, a monitoring of the plasma levels of lopinavir is strongly encouraged (see section
Ako se ta kombinacija ipak smatra potrebnom, valja pratiti vrijednosti lopinavira u plazmi (vidjeti dio 4.4).
In patients with renal or hepatic impairment, co-administration of colchicine in patients on Aptivus/ritonavir is contraindicated (see section 4.3).
U bolesnika s oštećenjem bubrega ili jetre koji primaju Aptivus/ritonavir, istodobna primjena kolhicina je kontraindicirana (vidjeti dio 4.3).
This can lead to death - Increased blood levels of bilirubin (a breakdown product of haemoglobin) You should inform your child's doctor if they experience: - Loss of appetite - Nausea (upset stomach) - Vomiting and/or jaundice which may be symptoms of abnormal liver function - Bleeding - * Bleeding in the brain.
Potrebno je obavijestiti djetetovog liječnika ako Vaše dijete ima: - gubitak apetita - mučninu - povraćanje i/ili žuticu koji mogu biti simptomi abnormalne funkcije jetre - Krvarenje - * krvarenje u mozgu, koje može dovesti do trajnog invaliditeta ili smrti, a pojavilo se u nekih bolesnika koji su se liječili Aptivusom u kliničkim ispitivanjima.
Coadministration of telaprevir with Aptivus/ritonavir is not recommended.
Istodobna primjena telaprevira s Aptivusom/ritonavirom se ne preporučuje.
Abdominal pain
Bol u abdomenu Osip
The concomitant use of Aptivus, coadministered with low dose ritonavir, with atazanavir/ritonavir is not recommended.
Istodobna primjena Aptivusa s niskom dozom ritonavira i atazanavira/ritonavira se ne preporučuje.
If the combination is nevertheless considered necessary, a monitoring of the plasma levels of saquinavir is strongly encouraged (see section
Ako se ta kombinacija ipak smatra potrebnom, valja pratiti vrijednosti sakvinavira u plazmi (vidjeti dio
Inhibition of CYP 3A4 by tipranavir/r.
Inhibicija CYP 3A4 putem tipranavira/r.
CYP 3A4 inhibition by tipranavir/r
CYP 3A4 inhibicija putem tipranavira/r
Abacavir 300 mg BID (TPV/r 750/100 mg BID)
Abakavir 300 mg BID (TPV/r 750/100 mg BID)
Coadministration of boceprevir with Aptivus/ritonavir is not recommended.
Istodobna primjena boceprevira s Aptivusom/ritonavirom se ne preporučuje.
Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir, is expected to increase flecainide, propafenone and metoprolol concentrations.
Temeljem teoretskih razmatranja, očekuje se da tipranavir u primjeni s niskom dozom ritonavira povećava koncentracije flekainida, propafenona i metoprolola.
H2-receptor antagonists No interaction study performed
Antagonisti H2-receptora
Mono/diglycerides of caprylic/capric acid Propylene glycol
Sadržaj kapsule makrogolglicerolricinoleat etanol mono/digliceridi kaprilatne/kaprinske kiseline propilenglikol pročišćena voda trometamol propilgalat
- omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole (proton pump inhibitors used to reduce the gastric acid production) - metronidazole (used to treat infections) - disulfiram (used to treat alcohol dependence) - buprenorphine/naloxone (medicines used to treat severe pain) - cyclosporin, tacrolimus, sirolimus (used to prevent organ rejection (to suppress the immune system)) - warfarin (used to treat and prevent thrombosis)
Ne smije se propisivati tadalafil dok ne prođe 7 ili više dana od početka primjene Aptivusa. - omeprazol, esomeprazol, lanzoprazol, pantoprazol, rabeprazol (inhibitori protonske pumpe koji se primjenjuju za smanjenje proizvodnje želučane kiseline) - metronidazol (primjenjuje se u liječenju infekcija) - disulfiram (primjenjuje se u liječenju ovisnosti o alkoholu) - buprenorfin/nalokson (lijekovi koji se primjenjuju u liječenje teške boli) - ciklosporin, takrolimus, sirolimus (primjenjuju se za sprječavanje odbacivanja organa (za supresiju imunološkog sustava)) - varfarin (primjenjuje se u liječenju i prevenciji tromboze) - digoksin (primjenjuje se u liječenju srčanih aritmija i zatajenja srca)
If a dose is missed by more than 5 hours, the patient should be instructed to wait and then to take the next dose of Aptivus and ritonavir at the regularly scheduled time.
U slučaju propuštanja doze za više od 5 sati, bolesnika je potrebno uputiti da pričeka na uzimanje sljedeće doze Aptivusa i ritonavira u redovno vrijeme prema režimu doziranja.
Antithrombotics Warfarin 10 mg QD First-dose tipranavir /r: S-warfarin Cmax ↔ S-warfarin AUC ↑ 18%
Prva doza tipranavira/r: S-varfarin Cmax ↔ S-varfarin AUC ↑ 18%
The concomitant use of Aptivus, co-administered with low dose ritonavir, with astemizole or terfenadine is contraindicated due to potential serious and/or life threatening events (see section 4.3)
Istodobna primjena Aptivusa s niskom dozom ritonavira i astemizola ili terfenadina je kontraindicirana zbog potencijalnih teških i/ili fatalnih događaja (vidjeti dio 4.3)
Anticonvulsants Carbamazepine 200 mg BID
Antitrombotici Varfarin 10 mg QD
Co-administration of bosentan and Aptivus with low dose ritonavir is not recommended (see section 4.4).
Istodobna primjena bosentana i Aptivusa s niskom dozom ritonavira se ne preporučuje (vidjeti dio 4.4)
Baseline CD4+ (cells/mm
Medijan promjene od početnog broja CD4+ stanica (stanice/mm
high liver function test results hepatitis B or C infection you are at increased risk of severe and potentially fatal liver damage while taking Aptivus.
Bolesnici s kroničnim hepatitisom B ili C liječeni kombiniranom antiretrovirusnom terapijom imaju povećan rizik teških i potencijalno fatalnih nuspojava od strane jetre.
The concomitant use of Aptivus, co-administered with low dose ritonavir, with amiodarone, bepridil or quinidine is contraindicated due to potential serious and/or life threatening events (see section 4.3)
Istodobna primjena Aptivusa s niskom dozom ritonavira i amiodarona, bepridila ili kinidina je kontraindicirana zbog potencijalnih teških i/ili fatalnih događaja (vidjeti dio 4.3)
Analyses were conducted to assess virological outcome by the number of primary PI mutations (any change at protease codons 30, 32, 36, 46, 47, 48, 50, 53, 54, 82, 84, 88 and 90) present at baseline.
Analiza virološkog odgovora u odnosu na broj primarnih mutacija IP (bilo koja promjena u proteaznim kodonima 30, 32, 36, 46, 47, 48, 50, 53, 54, 82, 84, 88 i 90) prisutnih na početku pokazala je da je stopa odgovora na tipranavir s ritonavirom bila veća nego na kontrolni tretman i u bolesnika s novouvedenim enfuvirtidom i u onih bez njega.
The concomitant use of Aptivus, co-administered with low dose ritonavir, with cisapride is contraindicated due to potential serious and/or life threatening events (see section 4.3)
Istodobna primjena Aptivusa s niskom dozom ritonavira i cisaprida je kontraindicirana zbog potencijalnih teških i/ili fatalnih događaja (vidjeti dio 4.3)
Zidovudine 300 mg BID (TPV/r 750/100 mg BID)
Zidovudin 300 mg BID (TPV/r 750/100 mg BID)
- bosentan (used to treat pulmonary artery hypertension) - halofantrine or lumefantrine (used to treat malaria) - tolterodine (used to treat overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence)) - boceprevir and telaprevir (used to treat hepatitis C) - cobicistat and products containing cobicistat (used to increase effectiveness of HIV medicines).
hitnosti mokrenja, ili hitnosti mokrenja s nemogućnosti zadržavanja mokraće)) - boceprevir i telaprevir (koji se primjenjuju u liječenju hepatitisa C) - kobicistat i lijekovi koji sadrže kobicistat (koji se primjenjuju za povećanje učinkovitosti lijekova protiv HIV-a).
Dosing of enteric-coated didanosine and Aptivus soft capsules, coadministered with low dose ritonavir, should be separated by at
Primjena želučano otporne formulacije didanozina i Aptivus mekih kapsula s niskom dozom ritonavira mora biti odvojena najmanje 2 sata radi izbjegavanja inkompatibilnosti formulacija.
Anaemia
Hemofilija
Antibiotics
Antiepileptici
Salmeterol
Metoprolol
When Aptivus/ritonavir is co-administered with telaprevir, a decrease or an increase of telaprevir exposure could be expected.
istodobno s telaprevirom,može se očekivati smanjena ili povećana izloženost telapreviru.
Limited data are currently available for the use of Aptivus, co-administered with low dose ritonavir, in patients co-infected with hepatitis B or C. Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reaction.
Podaci o primjeni Aptivusa i niske doze ritonavira, u bolesnika s istodobnom infekcijom virusom hepatitisa B ili C trenutno su ograničeni.
Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir, is expected to increase triazolam concentrations.
Temeljem teoretskih razmatranja očekuje se da tipranavir s niskom dozom ritonavira povećava koncentracije triazolama.
Be sure your child's doctor clearly informs you what the correct dose for your child should be. You should measure the exact dose using the supplied measuring syringe and adapter, as follows:
Vas je djetetov liječnik jasno obavijestio koja je ispravna doza za Vaše dijete.
NNRTIs
Antacidi
The concomitant use of Aptivus, coadministered with low dose ritonavir, with amprenavir/ritonavir is not recommended.
Istodobna primjena Aptivusa s niskom dozom ritonavira i amprenavira/ritonavira se ne preporučuje.
Tell your doctor if you have: - type A or B haemophilia - diabetes - liver disease.
A ili B - dijabetes - bolest jetre.
This may be in the skin or joints.
A i B, možete imati pojačano krvarenje, koje može biti u koži ili zglobovima.
Inhibition of CYP 3A4 by tipranavir/r
Inhibicija CYP 3A4 putem tipranavira/r
In order to achieve effective tipranavir plasma concentrations and a twice daily dosing regimen, coadministration of tipranavir with low dose ritonavir twice daily is essential (see section 4.2).
Tipranavir se mora primijeniti s niskom dozom ritonavira kako bi se osigurale djelotvorne koncentracije u plazmi i mogućnost doziranja dva puta dnevno (vidjeti dio 4.2).
The concomitant use of Aptivus, co-administered with low dose ritonavir, with triazolam is contraindicated due to potential serious and/or life threatening events (see section 4.3)
Istodobna primjena Aptivusa s niskom dozom ritonavira i triazolama je kontraindicirana zbog potencijalno teških i/ili fatalnih događaja (vidjeti dio 4.3)
Anti-HCV agents Boceprevir No interaction study performed
Lijekovi protiv HCV-a Boceprevir
The concomitant use of Aptivus, coadministered with low dose ritonavir, with lopinavir/ritonavir is not recommended.
Istodobna primjena Aptivusa s niskom dozom ritonavira i lopinavira/ritonavira se ne preporučuje.
The concomitant use of Aptivus, coadministered with low dose ritonavir, with saquinavir/ritonavir is not recommended.
Istodobna primjena Aptivusa s niskom dozom ritonavira i sakvinavira/ritonavira se ne preporučuje.
BSA Range (m
Površina tijela raspon (m
The comparator regimen included a ritonavir-boosted PI (also individually defined) plus an OBR.
Kontrolni tretman se sastojao od individualno odabranog inhibitora proteaze (IP) s ritonavirom dodanih uz OBR.
Inhibition of CYP 3A4 by atazanavir/ritonavir and induction by tipranavir/r.
Inhibicija CYP 3A4 putem atazanavir/ritonavira te indukcija putem tipranavira/r.
1184 cells/mm
stanica/mm
An interaction study in women between tipranavir, co-administered with low dose ritonavir, and ethinyl oestradiol/norethindrone demonstrated a high frequency of non-serious rash.
U ispitivanju interakcija s etinilestradiolom/noretindronom u žena, uz istodobnu primjenu tipranavira s niskom dozom ritonovira, povećala se učestalost blagog do umjereno teškog osipa.